Arvinas, Inc.
ARVNHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeArvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company carries a $516.2M market cap, placing it firmly in the small-cap category. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Market Cap
$516.2M
Beta
1.80
P/E (TTM)
—
P/E (Fwd)
-2.40
EPS (TTM)
$-3.18
EPS (Fwd)
$-3.33
ROE
-42.3%
ROA
-18.9%
Cash
$614.9M
Total Debt
$8.4M
Free CF
-$199.6M
52W Change
15.1%
Annual Financials
Cash vs Debt
Arvinas, Inc. holds $614.9M in cash against $8.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$199.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -42.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $131.4M to $262.6M.
A beta of 1.80 means ARVN is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Arvinas, Inc.'s trajectory.